NCT03744767View on ClinicalTrials.gov

Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 19, 2014

Primary Completion Date

September 22, 2015

Study Completion Date

September 22, 2015

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Spironolactone 50 MG

oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4

All Listed Sponsors
lead

Dr Irmela MANTEL

OTHER

NCT03744767 - Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter